| 000 | 01815 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514190338.0 | ||
| 264 | 0 | _c20051028 | |
| 008 | 200510s 0 0 ger d | ||
| 022 | _a0001-7868 | ||
| 024 | 7 |
_a10.1055/s-2004-818414 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDoehn, C | |
| 245 | 0 | 0 |
_a[Immunotherapy of renal cell carcinoma: results from current phase-III-trials]. _h[electronic resource] |
| 260 |
_bAktuelle Urologie _cApr 2004 |
||
| 300 |
_a121-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCancer Vaccines _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCytokines _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aInterferon-gamma _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 |
_aKidney _xpathology |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aJocham, D | |
| 773 | 0 |
_tAktuelle Urologie _gvol. 35 _gno. 2 _gp. 121-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1055/s-2004-818414 _zAvailable from publisher's website |
| 999 |
_c14855376 _d14855376 |
||